102153-63-9

Basic information

• Product Name: 6-Chloro-2-naphthylsulfonyl chloride
• Synonyms: 6-cloro-2-naphthylsulfonylchloride;6-CHLORO-NAPHTHALENE-2-SULFONYL CHLORIDE;6-CHLORO-2-NAPHTHYL SULFONYL CHLORIDE;2-Chloro-6-naphthalenesulfonyl chloride;6-Chloronaphthalene sulfonyl chloide;6-CHLORO-2-NAPHTHYLSULFONYL CHLORIDE,99% MIN;6-CHLORO-2-NAPHTHALENESULFONYLCHLORIDE;6-Cloro-2-Naphthylsulfonyl Chlorid
• CAS NO: 102153-63-9
• Molecular Formula: C₁₀H₆Cl₂O₂S
• Molecular Weight: 261.12
• Product Categories: Naphthalene series
• Mol File: 102153-63-9.mol

Chemical Properties

• Melting Point: 108 °C
• Boiling Point: 402.912 °C at 760 mmHg
• Flash Point: 197.474 °C
• Appearance: /
• Density: 1.517 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.65
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 6-Chloro-2-naphthylsulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-2-naphthylsulfonyl chloride(102153-63-9)
• EPA Substance Registry System: 6-Chloro-2-naphthylsulfonyl chloride(102153-63-9)

Safety Data

• Hazardous Substances Data: 102153-63-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
6-Chloro-2-naphthylsulfonyl chloride is used as a sulfonylating agent for the introduction of the 6-chloro-2-naphthylsulfonyl group into various organic molecules. Its application is crucial in selectively modifying the structures of these compounds, which is vital for the advancement of organic chemistry.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 6-Chloro-2-naphthylsulfonyl chloride is utilized as a key intermediate in the synthesis of certain pharmaceutical compounds. Its ability to selectively modify organic molecules contributes to the development of new drugs with improved therapeutic properties.
Used in Chemical Research:
6-Chloro-2-naphthylsulfonyl chloride is employed as a research tool in chemical laboratories for studying the reactivity and selectivity of sulfonyl chlorides in various chemical reactions. This helps in understanding the underlying mechanisms and contributes to the discovery of new reaction pathways and methodologies.
Used in Material Science:
In the field of material science, 6-Chloro-2-naphthylsulfonyl chloride is used for the functionalization of polymers and other materials. Its sulfonylating properties allow for the attachment of specific functional groups, which can enhance the properties of the materials for various applications, such as sensors, catalysts, and advanced materials.
Used in Agrochemical Industry:
6-Chloro-2-naphthylsulfonyl chloride is also utilized in the agrochemical industry for the synthesis of active ingredients in pesticides and herbicides. Its ability to modify organic molecules can lead to the development of more effective and targeted agrochemicals with reduced environmental impact.
Used in Dye and Pigment Industry:
In the dye and pigment industry, 6-Chloro-2-naphthylsulfonyl chloride is employed for the synthesis of novel dyes and pigments with improved colorfastness and stability. Its sulfonylating properties enable the attachment of specific functional groups, which can enhance the performance of these colorants in various applications, such as textiles, plastics, and inks.

InChI:InChI=1/C10H6Cl2O2S/c11-9-3-1-8-6-10(15(12,13)14)4-2-7(8)5-9/h1-6H

Upstream product

• 96416-46-5 -<6-(2-chlorsulfonyl-naphthyl-(6)-sulfon)-naphthyl-(2)>-sulfon 
• 102878-14-8 6-chloro-2-naphthalenesulphonic acid 
• 91-58-7 2-chloronaphthalene 
• 85-47-2 1-naphthalenesulfonic acid 

Downstream Products

• 1027580-02-4 6-Chloro-naphthalene-2-sulfonic acid [(S)-1-(3-cyano-benzyl)-2-oxo-pyrrolidin-3-yl]-amide 
• 2065-70-5 2,6-dichloronaphthalene 
• 229647-15-8 4-[(chloro-2-naphthalenyl)sulfonyl]-1-(phenylmethyl)-2-piperazinecarboxylic acid ethyl ester 
• 229646-37-1 4-(6-chloronaphthalen-2-ylsulfonyl)-1-[1-(pyridin-4-yl)piperidin-4-ylmethyl]piperazin-2-one 
• 705302-73-4 ethyl (R)-2-(benzyloxycarbonyl)amino-3-[(6-chloro-2-naphthalenylsulfonyl)amino]propionate 
• 207798-71-8 1-[(6-chloronaphthalen-2-yl)sulfonyl]-4-[4-(pyridin-4-yl)benzoyl]piperazine 
• 792172-61-3 1-[(6-chloro-2-naphthyl)sulfonyl]-4-[3-methoxy-4-(4-pyridyl)benzoyl]piperazine 
• 318986-28-6 8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-benzyl-spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one 
• 318986-40-2 1'-benzyloxycarbonyl-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one 
• 318987-57-4 1'-benzyloxycarbonyl-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid 
• 318987-58-5 ethyl 1'-benzyloxycarbonyl-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylate 
• 1021933-34-5 C₃₁H₃₂ClN₃O₈S 
• 203521-17-9 1-[(6-chloronaphthalen-2-yl]sulfonyl]piperazine 
• 724706-30-3 4-(6-chloro-naphthalene-2-sulfonyl)-piperazine-2-carboxylic acid cyclohexylmethyl-amide 

Relevant articles and documents

Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors

Factor Xa (FXa) is a trypsin-like serine protease involved in the coagulation cascade and has received great interest as a potential target for the development of new antithrombotic agents. Most of amidine-type FXa inhibitors reported have been found to s

Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites

Compound 7 was identified as the active metabolite of 6 by HPLC and mass spectral analysis. Modification of lead compound 7 by transformation of its N-oxide 6-6 biaryl ring system and fused aromatics produced a series of non-basic fXa inhibitors with excellent potency in anti-fXa and anticoagulant assays. The optimized compounds 73b and 75b showed sub to one digit micromolar anticoagulant activity (PTCT2). Particularly, anti-fXa activity was detected in plasma of rats orally administered with 1 mg/kg of compound 75b.

Substituted heterocyclic amides

This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermedia

Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 binding element

Our exploratory study was based on the concept that a non-amidine factor Xa (fXa) inhibitor is suitable for an orally available anticoagulant. We synthesized and evaluated a series of N-(6-chloronaphthalen-2-yl) sulfonylpiperazine derivatives incorporating various fused-bicyclic rings containing an aliphatic amine expected to be S4 binding element. Among this series, 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine type 61 displayed orally potent anti-fXa activity and evident prolongation of prothrombin time (PT) with the moderate bioavailability in rats. The X-ray crystal analysis afforded an obvious binding mode that 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c] pyridine and 6-chloronaphthalene respectively bound to S4 and S1 subsites. In this X-ray study, we discovered a novel intramolecular S-O close contact. Ab initio energy calculations of model compounds deduced that conformers with the most close S-O proximity were most stable. The Mulliken population analysis proposed that this energy profile was caused by both of electrostatic S-O affinity and N-O repulsion. The results of these calculations and X-ray analysis suggested a possibility that the restricted conformation effected the affinity to S4 subsite of fXa.

Orally active factor Xa inhibitors: 4,5,6,7-tetrahydrothiazolo[5,4-c] pyridine derivatives

In our investigation of factor Xa inhibitors, a series of 1-(6-chloronaphthalen-2-yl)sulfonyl-4-(4,5,6,7-tetrahydrothiazolo[5,4-c] pyridine-2-carbonyl)piperazines 3a-i were synthesized. In vitro inhibitory activities of the compounds against factor Xa and coagulation are summarized. Among the compounds, 3c and 3d, possessing a carbamoyl or N-methylcarbamoyl moiety, showed potent inhibitory activities when administered orally to rats.

Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents

Compounds of formula (I), wherein G1 is CH or N; G2 is CH or N; R1 is a variety of optional substituents, L1 is (1-4C)alkylene; T1 is CH or N; R2 and R3 are independently hydroge

Sulfonyl derivatives

Sulfonyl derivatives represented by general formula (I), salts of the same, and solvates of both: and application of them as drugs: [wherein R1is hydrogen, hydroxyl, nitro or the like; R2and R3are each independently hydrogen, halogeno or the like; R4and R5are each dependently hydrogen, halogeno or the like; Q1is an optionally substituted saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group or the like; Q2is a single bond, oxygen or the like; Q3is, e.g., a group represented by formula (a): T1is carbonyl or the like; and X1and X2are each independently methylidyne or nitrogen]. These compounds exhibit potent Fxa inhibiting activities and serve as excellent anticoagulants which speedily exert satisfactory and persistent anti-thrombotic effects through oral administration and little cause adverse effects.

Heterocyclic amides as inhibitors of factor Xa

This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediate

NOVEL SULFONYL DERIVATIVES

Sulfonyl derivatives represented by the following general formula (I): Q1-Q2-T1-Q3-SO2-QA and drugs containing the same (wherein Q1 is an optionally substituted, saturated or unsaturated, five- or six-membered cyclic hydrocarbon group, a five- or six-membered heterocyclic group, or the like; Q2 is a single band, oxygen, sulfur, C1-C6 alkylene or the like; QA is optionally substituted arylalkenyl, heteroarylalkenyl or the like; and T1 is carbonyl or the like). These compounds have potent FXa-inhibitory effects and promptly exert satisfactory and persistent antithrombotic effects through oral administration, thus being useful as anticoagulant agents little accompanied with side effects.

Use of oxido-squalene cyclase inhibitors to lower blood cholesterol

PCT No. PCT/GB96/01985 Sec. 371 Date Feb. 13, 1998 Sec. 102(e) Date Feb. 13, 1998 PCT Filed Aug. 14, 1996 PCT Pub. No. WO97/06802 PCT Pub. Date Feb. 27, 1997A compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein G, T1, T2 and T3 are selected from CH and N; provided that T2 and T3 are not both CH; A is selected from a direct bond and (1-4C)alkylene; X is selected from oxy, thio, sulphinyl, sulphonyl, carbonyl, carbonylamino, N-di-(1-6C)alkylcarbonylamino, sulphonamido, methylene, (1-4C)alkylmethylene and di-(1-6C)alkylmethylene, and when T2 is CH, X may also be selected from aminosulphonyl and oxycarbonyl; and Q is selected from (5-7C)cycloalkyl, a heterocyclic moiety containing up to 4 heteroatoms selected from nitrogen, oxygen and sulphur, phenyl, naphthyl, phenyl(1-4C)alkyl and phenyl(2-6C)alkenyl; for the manufacture of a medicament for treating diseases or medical conditions in which an inhibition of oxido-squalene cyclase is desirable.